ZB

Zura Bio Limited

ZURA·NASDAQ

$4.10

-5.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$266.59M
EPS-1.0600
P/E Ratio-4.97
Earnings Date08/13/2026

zura

Total Stockholders' Equity

Last Annual Value

101.54M

3-Year CAGR

73%

5-Year CAGR

-5%

10-Year CAGR

-2%

ZB

Zura Bio Limited Competitors Analysis of Total Stockholders' Equity

ZURA · NASDAQ
CompanyTotal Stockholders' Equity
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
101.54M
19.6%-4.9%N/A 
53.41M
-24.8%-27.2%N/A
122.17M
-30.8%-20.6%N/A
-17.51M
N/AN/AN/A
70.87M
N/A28.3%9.5%
306.13M
8.1%0.5%N/A
106.63M
N/AN/AN/A
218.48M
34.1%7.0%N/A
123.27M
-4.0%-15.0%N/A
111.38M
6.9%N/AN/A
206.75M
71.3%4.1%10.0%
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.1, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $4.1